
    
      Patients with Parkinson's disease with motor complications on levodopa therapy who completed
      the prior double-blind studies 6002-EU-007, 6002-US-013 or 6002-US-018 are eligible to enter
      into this 1-year, long-term open safety study with a starting istradefylline dose of 40mg per
      day.
    
  